

# Request title: Cancer and Drugs (specified)

Date of Response: 14 July

Further to your Freedom of Information request, the Trust has answered your questions in the order they appear in your request.

## Request

Within your organisation, how many patients have been treated for the following cancers and with the specified drugs within the last twelve months?

Please use the tables below for your convenience.

### Differentiated Non-Medullary Thyroid Cancer

Therapy	Axitinib (Inlyta)	Carbozantinib (Cometriq)	Pazopanib (Votrient)	Sorafenib (Nexavar)	Sunitinib (Sutent)	Vandetanib (Caprelsa)
Patients	0	0	0	0	0	0

### Advanced Prostate Cancer (response based on C61X (Malignant neoplasm of prostate))

Therapy	Abiraterone (Zytiga)	Cabazitaxel (Jevtana)	Docetaxel (Taxotere)	Enzalutamide (Xtandi)	Radium-223 (Xofigo)	Bicalutamide (Casodex)
Patients	69	11	31	45	0	0

### Hepatocellular Carcinoma (HCC)

Therapy	Bevacizumab (Avastin)	Everolimus (Afinitor)	Lapatinib (Tyverb)	Sorafenib (Nexavar)	Sunitinib (Sutent)
Patients	0	0	0	0	0

### Gastrointestinal Stromal Tumours (GISTs)

Therapy	Dasatinib (Sprycel)	Imatinib (Glivec)	Nilotinib (Tasigna)	Pazopanib (Votrient)	Regorafenib (Stivarga)	Sorafenib (Nexavar)	Sunitinib (Sutent)
Patients	0	13	0	0	0	0	0

## Reply

The Trust has answered your questions in the table above.

PLEASE NOTE: The Trust is unable to separate the prostate patients into just the advanced patients using the data that it has available. If a patient was given more than one during the period they will be counted in more than one category.